STLN compared with AHCO: revenue, margins and what each company keeps, and the suppliers and customers both name

STLNStarling Oncology, Inc.

Mkt capRevenueRevenue

AHCOAdaptHealth Corp.

Mkt capRevenueRevenue

Compare

STLNStarling Oncology, Inc.

AHCOAdaptHealth Corp.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

STLN1 of 4 reports

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±32.7%▼−45.97%×1.41

AHCO

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±20.9%▲+6.26%×0.30

Q2 FY26±13.5%▼−38.04%×2.81

= impliedSTLN realized, solidAHCO realized, hatchedOne scale, both sides: full bar = 46%× = |realized| ÷ impliedSource: market data

Q1 FY26

±11.7%

▼−9.89%

×0.85

Feb 24 '26±12.4%▼−13.95%×1.12

STLNStarling Oncology, Inc.

3.59▼−46.36%· post 3.62

Mkt cap$369.2MRevenue$170MQ3 FY26Revenue$503MFY25

AHCOAdaptHealth Corp.

7.34▼−0.94%· post 7.34

ClosedNov 6 '26

Mkt cap$1.0BRevenue$746MQ3 FY26Revenue$3.1BFY25

Compare

ClosedNov 6 '26

STLNStarling Oncology, Inc.

AHCOAdaptHealth Corp.

3.59▼−46.36%post 3.62

Price

7.34▼−0.94%post 7.34

$369.2M

Mkt cap

$1.0B

Q3 FY26$170M

Revenue

$746MQ3 FY26

FY25$503M

Revenue

$3.1BFY25

STLN3.59▼−46.36%vsAHCO7.34▼−0.94%ClosedNov 6 '26